ACTEMRA® (tocilizumab) has over 10 years of experience across multiple diseasesa,b
aIncludes FDA-approved uses for conditions other than SSc-ILD.
bIncludes only Phase III and Phase IV studies.
aIncludes FDA-approved uses for conditions other than SSc-ILD.
bIncludes only Phase III and Phase IV studies.
ACTEMRA has been used to treat 1,600,000+ people worldwidec
cAccording to the ACTEMRA Periodic Benefit-Risk Evaluation Report (PBRER). The 1,600,000+ number includes patients treated during clinical trials and in medical practices through April 10, 2020. Patients treated in medical practices is estimated based on the volume of product sold.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.